RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

November 20, 2025j3ff1

RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement

November 19, 2025j3ff1

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement 

November 18, 2025j3ff1

RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock

November 18, 2025j3ff1

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

February 10, 2025j3ff1

5/29/24 – RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

May 29, 2024j3ff1

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

March 26, 2024j3ff1

RespireRx-SCI-Bladder-paper-final-approved-for-distributionDownload

2/13/24 – RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

February 13, 2024j3ff1

1/22/24 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

January 22, 2024j3ff1

1/4/24 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient

January 4, 2024j3ff1

12/11/23 – RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

December 11, 2023j3ff1

10/12/23 – RespireRx Pharmaceutical Inc’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services

October 12, 2023j3ff1

8/9/23 – RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

August 9, 2023j3ff1

5/24/23 – ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

May 24, 2023j3ff1

4/5/23 – RespireRx Pharmaceuticals Inc. Establishes Research Collaboration with University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

April 5, 2023j3ff1

4/3/23 – RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation

April 3, 2023j3ff1

3/28/23 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Joseph Siegelbaum as an Independent Member of the Board of Directors

March 28, 2023j3ff1

3/1/23 – ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd

March 1, 2023j3ff1

2/1/23 – ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits

February 1, 2023j3ff1

1/23/23 – RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois

January 23, 2023j3ff1

1/12/23 – RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform

January 23, 2023j3ff1

12/5/22 – RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development

December 5, 2022j3ff1

11/17/22 – RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Sleep Apnea

November 17, 2022j3ff1

11/10/22 – RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4

November 10, 2022j3ff1

11/7/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th Meridian Drug Discovery Summit

November 8, 2022j3ff1

9/7/22 – ResolutionRx Slide Deck Re-Purposing Dronabinol

September 25, 2022j3ff1

8/8/22 – RespireRx Pharmaceuticals Inc. Announces that Sleep Review has Discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition

August 8, 2022j3ff1

5/24/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit

May 24, 2022j3ff1

5/17/22 – RespireRx Pharmaceuticals Inc. Announces RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics

May 17, 2022j3ff1

5/16/22 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus

May 16, 2022j3ff1

3/29/22 – WATCH: RespireRx Interim CEO Discusses Provisional Application for a Novel Lipid-Based Formulation Technology (LFT)

March 29, 2022j3ff1

3/24/2022 – Media Coverage: RespireRx Pharmaceuticals files provisional patent that may improve solubility of poorly soluble drugs

March 24, 2022j3ff1

3/23/2022 – RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol

March 23, 2022j3ff1

3/17/22 – Media Coverage: RespireRx Pharmaceuticals newest GABAkine

March 17, 2022j3ff1

3/16/22 – RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality

March 16, 2022j3ff1

3/10/22 – Proactive Investors: RespireRx Pharmaceuticals is developing innovative and revolutionary treatments to combat neuronal signaling disorders

March 10, 2022j3ff1